These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12382509)

  • 1. KS Biomedix licenses TransMID brain cancer product to Nycomed in European collaboration.
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):481. PubMed ID: 12382509
    [No Abstract]   [Full Text] [Related]  

  • 2. Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine.
    Rainov NG; Söling A
    Curr Opin Mol Ther; 2005 Oct; 7(5):483-92. PubMed ID: 16248284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials referral resource. Multicenter phase I and II trials in adults with high-grade gliomas.
    Kaplan RS; Smiley JK; Cheson BD
    Oncology (Williston Park); 1999 Apr; 13(4):532-3, 537. PubMed ID: 10234703
    [No Abstract]   [Full Text] [Related]  

  • 4. The closure of Sugen.
    Levitzki A
    Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548
    [No Abstract]   [Full Text] [Related]  

  • 5. European collaboration in trials of new agents for children with cancer.
    Ablett S; Doz F; Morland B; Vassal G; ;
    Eur J Cancer; 2004 Aug; 40(12):1886-92. PubMed ID: 15288291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy for brain tumor.
    Walker MD
    Int Adv Surg Oncol; 1980; 3():351-69. PubMed ID: 7005101
    [No Abstract]   [Full Text] [Related]  

  • 7. Current and future directions for Phase II trials in high-grade glioma.
    Alexander BM; Lee EQ; Reardon DA; Wen PY
    Expert Rev Neurother; 2013 Apr; 13(4):369-87. PubMed ID: 23545053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deal-making trends in oncology.
    Moore K; Walker J
    Nat Rev Drug Discov; 2009 Aug; 8(8):604. PubMed ID: 19644466
    [No Abstract]   [Full Text] [Related]  

  • 9. Commentary on "European collaboration in trials of new agents for children with cancer" by Ablett et al.
    Smith MA; Anderson BD
    Eur J Cancer; 2004 Aug; 40(12):1893-5. PubMed ID: 15288292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiochemotherapy of malignant glioma in adults. Clinical experiences.
    Kortmann RD; Jeremic B; Weller M; Plasswilm L; Bamberg M
    Strahlenther Onkol; 2003 Apr; 179(4):219-32. PubMed ID: 12707711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACCESS oncology and Zentaris sign product partnership.
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):484. PubMed ID: 12382516
    [No Abstract]   [Full Text] [Related]  

  • 12. Pot of gold for glioma therapy.
    Piomelli D
    Nat Med; 2000 Mar; 6(3):255-6. PubMed ID: 10700220
    [No Abstract]   [Full Text] [Related]  

  • 13. Concurrent chemoradiotherapy for malignant glioma: dead end or highway?
    Mirimanoff RO
    Onkologie; 2008 Sep; 31(8-9):430-1. PubMed ID: 18787348
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical significance of mustoforan in management of malignant glioma].
    Kobiakov GL
    Vopr Onkol; 2007; 53(6):724-9. PubMed ID: 18416147
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
    Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
    Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value creation and sharing among universities, biotechnology and pharma.
    Edwards MG; Murray F; Yu R
    Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
    [No Abstract]   [Full Text] [Related]  

  • 17. [Local chemotherapy of malignant glioma: from syringe injections to nanotechnology].
    Petit S; Garcion E; Benoit JP; Menei P
    Rev Neurol (Paris); 2008; 164(6-7):547-53. PubMed ID: 18565353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value drivers in licensing deals.
    Arnold K; Coia A; Saywell S; Smith T; Minick S; Löffler A
    Nat Biotechnol; 2002 Nov; 20(11):1085-9. PubMed ID: 12410249
    [No Abstract]   [Full Text] [Related]  

  • 19. The George C. Cotzias Laboratory of Neuro-Oncology.
    Hadden JW
    Clin Bull; 1980; 10(4):167-71. PubMed ID: 6260397
    [No Abstract]   [Full Text] [Related]  

  • 20. New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology.
    Brandes AA; Franceschi E
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1129-31. PubMed ID: 16925479
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.